Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-Label, Multicentre Dose-Escalation Study to Investigate the Safety and Pharmacokinetics of AZD5312 in Patients With Advanced Solid Tumours Where the Androgen Receptor Pathway is a Potential Factor

NCT02144051 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02144051
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02144051 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-Label, Multicentre Dose-Escalation Study to Investigate the Safety and Pharmacokinetics of AZD5312 in Patients With Advanced Solid Tumours Where the Androgen Receptor Pathway is a Potential Factor
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2014
Completion date
March 31, 2016
Enrollment
32 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumours with androgen receptor pathway as a potential factor